AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00004188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV
Study NCT00004188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00004188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00004188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00004188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00004188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00004188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotretinoin
Description: Given IV
Study NCT00004188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study NCT00004188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV
Study NCT00004188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00004188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Study NCT00004188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support
Study NCT00004188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: All patients undergo delayed surgical resection of the residual tumor after course 5 of induction chemotherapy
Study NCT00004188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00004188 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: After completion of consolidation (at least 28 days from stem cell infusion), all patients receive local radiotherapy daily over 7 days
Study NCT01543867 — intervention group
Intervention type: DRUG
Intervention: somatropin
Description: Prescribed at the discretion of the treating physician according to product labelling
Study NCT02498249 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: Will be performed irradiation with low-intensity laser in upper trapezius muscle
Study NCT02498249 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo low level laser therapy
Description: Will be not performed irradiation with low-intensity laser in upper trapezius muscle
Study NCT04593147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BBN
Description: BBN to be fed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
Study NCT04593147 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brand
Description: Brand to be fed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks
Study NCT03610919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Sprays
Description: Intranasal administration of 24 international units per dose.
Study NCT03610919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nasal Sprays
Description: Intranasal administration of 24 international units per dose.
Study NCT00687882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shortened duration (6 weeks) of anticoagulant therapy
Description: Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 6 weeks.
Study NCT00687882 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional duration (3 months) of anticoagulant therapy
Description: Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 3 months.
Study NCT00687882 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: Subjects with evidence of persistent thrombus at 6 weeks time will remain on anticoagulant therapy for 3-6 months at the discretion of their treating physician.
Study NCT00687882 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: Subjects with evidence of persistent antiphospholipid antibody at 6 weeks will remain on anticoagulant therapy for 3 months to indefinite duration, at the discretion of their treating physician.
Study NCT04333381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational and organizational intervention
Description: Patients included after a systematic educational and organizational intervention for early diagnosis and care in myocardial infarction, aimed at emergency nurses of a tertiary Hospital capable in primary PCI.~1. The educational intervention will consist:~   Systematized educational intervention on acute myocardial infarction for emergency triage nurses will consist of theoretical and practical training through case presentations and clinical simulation.~2. The organizational intervention will consist:~   * Development and dissemination of an early diagnostic tool for acute myocardial infarction: STEMI infographics. It will be provided to all emergency nurses and emergency triage boxes~  * Update the STEMI hospital protocol and adapt it to the current clinical guidelines of the European Society of Cardiology (ESC)~  * Review organizational strategies and definition of new improvement measures~  * Audit the delays in STEMI~  * Periodic multi-disciplinary update sessions
Study NCT04333381 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Common Practice
Description: Common practice is based on care by emergency nurses who did not receive any systematized education of acute myocardial infarction led by interventional cardiology nurses. On the other hand, emergency management is based on Plan-Do-Study-Act methodology and in the historical sample some organizational improvement strategies did not exist or were beginning to be implemented
Study NCT00964106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine dosed at 100 mg as probe for CYP1A2 pathway
Study NCT00964106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Dosed at 4 mg as probe for CYP2C8 pathway
Study NCT00964106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Description: Dosed at 40 mg, probe for CYP2C9 pathway
Study NCT00964106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Dosed at 20 mg, probe for CYP2C19 pathway
Study NCT00964106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Dosed at 30 mg, probe for CYP2D6 pathway
Study NCT00964106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Dosed at 3 mg for Part 1, Part 2 cohorts B and C and 1 mg for Part 2 Cohort A, probe drug for CYP3A4/5 pathway
Study NCT00964106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Dosed at 10 mg, probe drug for OATP1B1 pathway
Study NCT00964106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Dosed at 400 mg once-daily Day 1 through Day 9, inhibitor of CYP3A4
Study NCT00964106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Dosed at 400 mg x 1 dose on day 1, 200 mg once daily on days 2 through 9, inhibitor of CYP2C9 pathway
Study NCT00964106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Dosed at 600 mg x 1 dose on Day 1 and Day 8, inhibitor of OATP1B1 pathway
Study NCT00964106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Dosed at 15 mg, probe drug for CYP2C8 pathway
Study NCT02103582 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intervention
Description: Participants who are randomized to the 'intervention arm' will be asked to come to the study site to exercise 3 days per week for 12 weeks. The exercise duration will increase over time from 75 minutes per week to 150 minutes per week. Intervention participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Intervention participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
Study NCT02103582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Participants who are randomized to the 'intervention arm' will be asked to come to the study site to exercise 3 days per week for 12 weeks. The exercise duration will increase over time from 75 minutes per week to 150 minutes per week. Intervention participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Intervention participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
Study NCT02425501 — intervention group
Intervention type: DRUG
Intervention: Aflibercept (Eylea, BAY86-5321)
Description: Administration by intravitreal injection
Study NCT01706718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bread
Study NCT01706718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bread
Study NCT02285205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral administration of Lobeglitazone
Description: Lobeglitazone 0.5mg/tablet, orally, 1 tablet once daily for 24 weeks
Study NCT00442546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: 150 milligram (mg)/ day (double blind)
Study NCT00174629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel/DDP
Study NCT01212107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphate Binders
Study NCT00174629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel/gemcitabine
Study NCT01613885 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This study does not involve any intervention other than obtaining blood, nasal/cheek/throat/skin swabs, saliva, sputum, urine, and stool samples, breathing and skin tests.
Study NCT01096251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT vs BST
Description: The comparison between the CBT and BST will be assessed in a two-arm randomized controlled trial. Participants will be randomly allocated in 2 groups (CBT and BST).
Study NCT04392076 — intervention group
Intervention type: PROCEDURE
Intervention: Image Guided Ablation
Description: Image Guided Ablation with RFA, MWA or CRYO of Renal Cancer
Study NCT03423979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optilume™ BPH Prostatic DCB Dilation Catheter
Description: BPH Prostatic DCB treatment - The Optilume BPH Prostatic DCB Dilation Catheter System should be prepared per the Instructions for Use (IFU).
Study NCT03423979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel will release to adjacent tissue after the balloon inflated in the urethra
Study NCT01400412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Darunavir was administered orally once a day as two 400 mg tablets with food. When the 800 mg formulation tablet became available, it was substituted for the two 400 mg tablet.
Study NCT01400412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir was administered orally together with darunavir as one 100 mg tablet once daily with food.
Study NCT01400412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: Tenofovir disoproxil fumarate was administered orally as one 300 mg tablet once a day.
Study NCT01400412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: Emtricitabine was administered orally once a day as one 200 mg capsule.
Study NCT01400412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Tenofovir disoproxil fumarate
Description: Placebo for tenofovir disoproxil fumarate was administered orally once a day as one tablet.
Study NCT01400412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Maraviroc
Description: Placebo for maraviroc was administered orally once a day as one tablet.
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vindesine
Description: see detailed protocol description
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vindesine
Description: see detailed protocol description
Study NCT01400412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc was administered orally once a day as one 150 mg tablet.
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunoxome
Description: see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
Study NCT02586194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: Oral
Study NCT03325049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The health-promoting conversations
Description: The health-promoting conversations
Study NCT03325049 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care
Study NCT04295772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOR/ISL
Description: 100 mg DOR/0.75 mg ISL FDC tablet taken once daily by mouth.
Study NCT01604187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Ten minutes before the procedure fentanyl sublingual tablet (Abstral ® 100 µg, ProStrakan) will be given to the patient.
Study NCT01604187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ten minutes before the procedure placebo sublingual tablet will be given to the patient.
Study NCT00492050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.6 mg/m\^2 IV Weekly on Days 1, 8, 15 and 22.
Study NCT00492050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 IV on Day 8 and 22.
Study NCT00492050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: 500 mg orally daily (or acyclovir 200 mg orally twice daily)
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunoxome
Description: see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine
Description: see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
Study NCT03612531 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Receive manual therapy
Study NCT01189851 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intraoperative Radiotherapy
Description: The Axxent eBx™ System utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed and provides brachytherapy when the physician chooses to deliver intracavitary or interstitial radiation to the surgical margins following lumpectomy for breast cancer.
Study NCT03511664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles. After 4 cycles, patients were assessed for (1) evidence of response, (2) residual disease, and (3) tolerance to 177Lu-PSMA-617. If all 3 assessments were met the patient might received an additional 2 cycles of 177Lu-PSMA-617.
Study NCT03511664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive/best standard of care
Description: Best supportive/best standard of care as defined by the local investigator
Study NCT03511664 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best supportive/best standard of care
Description: Best supportive/best standard of care as defined by the local investigator
Study NCT04442139 — intervention group
Intervention type: OTHER
Intervention: Mini-Gastric Bypass
Description: Mini-Gastric Bypass bariatric surgery
Study NCT00769522 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: cycle 1: 375 mg/m² i.v., day 0, q28d~cycle 2-6: 500 mg/m² i.v., day 1, q28d
Study NCT00769522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: cycle 1-6: 90mg/m² i.v., day 1-2, q28d
Study NCT00769522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cycle 1-6: 250 mg/m² i.v., days 1-3, q28d
Study NCT00769522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: cycle 1-6: 25 mg/m² i.v., days 1-3, q28d
Study NCT02096237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IgE adsorber
Description: Two plasma volumes of each patient in the apheresis group will be treated per session
Study NCT03577288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: manipulation of the level of realism
Description: The realism of the virtual experience will be manipulated. In one condition the realism will be high and in another condition the realism will be low. In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., high realism with negative stimuli, low realism with negative stimuli, high realism with positive stimuli).~The measures of the pupillary responses, gaze fixation, heart rate, head movement (only in part A) and Late Positive Potential (EEG - only in part B) will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion.
Study NCT03577288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: manipulation of the presence and size of avatar
Description: The presence of avatar in the virtual experience will be manipulated. In one condition the avatar will be present and in another condition the avatar will not be present. In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., with avatar and negative stimuli, without avatar and negative stimuli, with avatar and positive stimuli, etc.).~Children will be exposed to only one of the two possible situations: with an avatar or without an avatar for the entire experience. Adults will be exposed to only one of the four possible situations: with standard size avatar, with giant avatar, with tiny avatar, or without avatar.~The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion.
Study NCT03577288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: manipulation of interaction
Description: Virtual experience condition will be manipulated. In one condition the participants will be exposed to the virtual experience in which they will be able to interact with some of the stimuli, in another condition they will not be able to interact with the stimuli (passive watching). In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., interaction possible - negative stimuli, interaction impossible - negative stimuli, interaction possible - positive stimuli).~The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion.
Study NCT03577288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: manipulation of the nature of stimulus
Description: The nature of the stimuli with which the participants will interact will be manipulated. During virtual experience the participants will have a choice to interact or not with the virtual environment, in one condition with animate stimuli and in another condition with inanimate stimuli. In addition, emotional category of animate and inanimate stimuli will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., condition with animate negative stimuli, condition with inanimate negative stimuli, condition with animate positive stimuli). The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion.
Study NCT01117441 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: for eligibility for radiotherapy see detailed protocol description
Study NCT01117441 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: for eligibility for radiotherapy see detailed protocol description